Functional improvement of mutant keratin cells on addition of desmin: an alternative approach to gene therapy for dominant diseases
- PMID: 15215887
- DOI: 10.1038/sj.gt.3302301
Functional improvement of mutant keratin cells on addition of desmin: an alternative approach to gene therapy for dominant diseases
Abstract
A major challenge to the concept of gene therapy for dominant disorders is the silencing or repairing of the mutant allele. Supplementation therapy is an alternative approach that aims to bypass the defective gene by inducing the expression of another gene, with similar function but not susceptible to the disrupting effect of the mutant one. Epidermolysis bullosa simplex (EBS) is a genetic skin fragility disorder caused by mutations in the genes for keratins K5 or K14, the intermediate filaments present in the basal cells of the epidermis. Keratin diseases are nearly all dominant in their inheritance. In cultured keratinocytes, mutant keratin renders cells more sensitive to a variety of stress stimuli such as osmotic shock, heat shock or scratch wounding. Using a 'severe' disease cell culture model system, we demonstrate reversion towards wild-type responses to stress after transfection with human desmin, an intermediate filament protein normally expressed in muscle cells. Such a supplementation therapy approach could be widely applicable to patients with related individual mutations and would avoid some of the financial obstacles to gene therapy for rare diseases.
Similar articles
-
Supplementation of a mutant keratin by stable expression of desmin in cultured human EBS keratinocytes.J Cell Sci. 2000 Dec;113 Pt 23:4231-9. doi: 10.1242/jcs.113.23.4231. J Cell Sci. 2000. PMID: 11069768
-
Characterization of immortalized human epidermolysis bullosa simplex (KRT5) cell lines: trimethylamine N-oxide protects the keratin cytoskeleton against disruptive stress condition.J Dermatol Sci. 2009 Mar;53(3):198-206. doi: 10.1016/j.jdermsci.2008.11.003. Epub 2009 Jan 20. J Dermatol Sci. 2009. PMID: 19157792
-
Keratin 14-null cells as a model to test the efficacy of gene therapy approaches in epithelial cells.J Invest Dermatol. 2011 Jul;131(7):1412-9. doi: 10.1038/jid.2011.19. Epub 2011 Feb 17. J Invest Dermatol. 2011. PMID: 21326298
-
Epidermolysis bullosa simplex.Semin Dermatol. 1993 Sep;12(3):173-90. Semin Dermatol. 1993. PMID: 7692916 Review.
-
Mutation analysis of the entire keratin 5 and 14 genes in patients with epidermolysis bullosa simplex and identification of novel mutations.Hum Mutat. 2003 Apr;21(4):447. doi: 10.1002/humu.9124. Hum Mutat. 2003. PMID: 12655565 Review.
Cited by
-
Ideal Living Skin Equivalents, From Old Technologies and Models to Advanced Ones: The Prospects for an Integrated Approach.Biomed Res Int. 2024 Aug 16;2024:9947692. doi: 10.1155/2024/9947692. eCollection 2024. Biomed Res Int. 2024. PMID: 39184355 Free PMC article. Review.
-
The molecular basis of human keratin disorders.Hum Genet. 2009 May;125(4):355-73. doi: 10.1007/s00439-009-0646-5. Epub 2009 Feb 27. Hum Genet. 2009. PMID: 19247691 Review.
-
An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex.Br J Dermatol. 2019 Jan;180(1):141-148. doi: 10.1111/bjd.17075. Epub 2018 Oct 7. Br J Dermatol. 2019. PMID: 30099737 Free PMC article.
-
Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise.Exp Dermatol. 2012 Jul;21(7):481-9. doi: 10.1111/j.1600-0625.2012.01534.x. Exp Dermatol. 2012. PMID: 22716242 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous